2022
DOI: 10.1016/j.cjac.2022.100123
|View full text |Cite
|
Sign up to set email alerts
|

Review of analytical and bioanalytical techniques for the determination of first-line anticytomegalovirus drugs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 85 publications
0
2
0
Order By: Relevance
“…Valganciclovir (VGC) is a firstline antiviral drug that is used for the treatment of CMV infections. 1,2 After oral administration, it undergoes hydrolysis in the intestine by hepatic esterase, which is a hydrolase enzyme, and is rapidly converted into ganciclovir (i.e., VGC is a prodrug of ganciclovir). 3,4 This drug was approved by the Food and Drug Administration in the year 2001 for the treatment of CMV infections.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Valganciclovir (VGC) is a firstline antiviral drug that is used for the treatment of CMV infections. 1,2 After oral administration, it undergoes hydrolysis in the intestine by hepatic esterase, which is a hydrolase enzyme, and is rapidly converted into ganciclovir (i.e., VGC is a prodrug of ganciclovir). 3,4 This drug was approved by the Food and Drug Administration in the year 2001 for the treatment of CMV infections.…”
Section: Introductionmentioning
confidence: 99%
“…Cytomegalovirus (CMV) is a virus that is associated with serious conditions such as mononucleosis and hepatitis in immunocompromised patients. Valganciclovir (VGC) is a first-line antiviral drug that is used for the treatment of CMV infections. , After oral administration, it undergoes hydrolysis in the intestine by hepatic esterase, which is a hydrolase enzyme, and is rapidly converted into ganciclovir (i.e., VGC is a prodrug of ganciclovir). , This drug was approved by the Food and Drug Administration in the year 2001 for the treatment of CMV infections. The major side effect of VGC is a decrease in the function of bone marrow, which leads to a drop in the level of blood cells (e.g., RBCs, WBCs, and platelets) and a decrease in the body’s immune response.…”
Section: Introductionmentioning
confidence: 99%